Therma Bright (TSE:THRM) has released an update.
Therma Bright Inc. has achieved a significant milestone with the FDA’s approval of its Venowave VW5 device, meeting a crucial CMS requirement for permanent coding. The Venowave VW5, a medical device aiding in the treatment of circulatory issues like DVT and PE, is now poised for distribution to Medicare and Medicaid practitioners. Additionally, Therma Bright has initiated a marketing drive to heighten investor relations and public awareness by partnering with OTBC for social media and online marketing services.
For further insights into TSE:THRM stock, check out TipRanks’ Stock Analysis page.
